NIMOTUZUMAB INDUCED HYPERTENSION(NIH): A MAIDEN CASE REPORT

Balaji O; Amita D; Navin Patil

doi:10.22159/ajpcr.2017.v10i4.16868

Authors

Balaji O Post graduate , Department of Pharmacology, Kasturba Medical college , Manipal university , Manipal.
Amita D Post graduate , Department of Pharmacology, Kasturba Medical college , Manipal university , Manipal.
Navin Patil Assistant Professor, Department of Pharmacology, Kasturba Medical college , Manipal university , Manipal.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i4.16868

Abstract

ABSTRACT

Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Nimotuzumab is one among the latest humanized monoclonal antibody targeting against Epidermal Growth Factor Receptor (EGFR). It is approved for Head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and Nasopharyngeal cancer in China. Hypertension is most common with Bevacizumab and Cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of Nimotuzumab induced hypertension in a 70-year-old man treated for vocal cord carcinoma.

Â

KEYWORDS: Nimotuzumab, Hypertension, EGFR, Adverse effects.

Downloads

Download data is not yet available.

References

Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. InMAbs 2009 Jan 1 (Vol. 1, No. 1, pp. 41-48). Taylor & Francis.

Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. InSeminars in nephrology 2010 Nov 30 (Vol. 30, No. 6, pp. 591-601). WB Saunders.

Fakih, M., & Vincent, M. (2010). Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Current Oncology, 17(Suppl 1), S18â€“S30.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, RobertsEA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-45.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992; 49:2229â€“32.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm.1992; 27:538